Marker Therapeutics is trading 14.35% up at $1.33 after biotech-sector strength lifted risk appetite on August 19, 2026.
- Trading at $1.33 (+14.35%)
- XBI is up 3.73% during regular trading following positive Moderna-Merck personalized cancer-vaccine trial results.
- No clearly confirmed company-specific announcement was found; H.C. Wainwright’s previously reiterated Buy rating and $10 target were not explicitly linked to today’s move.